[go: up one dir, main page]

DE69835225D1 - Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen - Google Patents

Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen

Info

Publication number
DE69835225D1
DE69835225D1 DE69835225T DE69835225T DE69835225D1 DE 69835225 D1 DE69835225 D1 DE 69835225D1 DE 69835225 T DE69835225 T DE 69835225T DE 69835225 T DE69835225 T DE 69835225T DE 69835225 D1 DE69835225 D1 DE 69835225D1
Authority
DE
Germany
Prior art keywords
glycocorticoidal
disorder
treatment
psychoses caused
psychoses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835225T
Other languages
English (en)
Other versions
DE69835225T2 (de
Inventor
F Schatzberg
K Belanoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of DE69835225D1 publication Critical patent/DE69835225D1/de
Publication of DE69835225T2 publication Critical patent/DE69835225T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69835225T 1997-10-06 1998-10-05 Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen Expired - Lifetime DE69835225T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6097397P 1997-10-06 1997-10-06
US60973P 1997-10-06
PCT/US1998/020906 WO1999017779A1 (en) 1997-10-06 1998-10-05 Methods for treating psychosis associated with glucocorticoid related dysfunction

Publications (2)

Publication Number Publication Date
DE69835225D1 true DE69835225D1 (de) 2006-08-24
DE69835225T2 DE69835225T2 (de) 2007-07-05

Family

ID=22032889

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835225T Expired - Lifetime DE69835225T2 (de) 1997-10-06 1998-10-05 Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen

Country Status (17)

Country Link
US (2) US6150349A (de)
EP (1) EP1023074B1 (de)
JP (3) JP2001518509A (de)
KR (2) KR100840957B1 (de)
CN (3) CN1528315A (de)
AT (1) ATE332696T1 (de)
AU (1) AU747956B2 (de)
CA (1) CA2302586C (de)
CY (1) CY1106330T1 (de)
DE (1) DE69835225T2 (de)
DK (1) DK1023074T3 (de)
ES (1) ES2268792T3 (de)
IL (2) IL135469A0 (de)
NO (1) NO327233B1 (de)
NZ (1) NZ503250A (de)
PT (1) PT1023074E (de)
WO (1) WO1999017779A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (de) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
JP2004509131A (ja) * 2000-09-18 2004-03-25 アプライド　リサーチ　システムズ　エーアールエス　ホールディング　ナームロゼ　フェンノートシャップ ２１−ヒドロキシ−６，１９−オキシドプロゲステロン（２１ｏｈ−６ｏｐ）の製造方法
JP2004525135A (ja) 2001-03-23 2004-08-19 コーセプト セラピューティクス， インコーポレイテッド 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
DE60238671D1 (de) * 2001-05-04 2011-02-03 Corcept Therapeutics Inc Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
WO2003009853A1 (en) * 2001-07-23 2003-02-06 Corcept Therapeutics, Inc. Methods for preventing antipsychotic-induced weight gain
WO2003020216A1 (en) 2001-08-31 2003-03-13 Corcept Therapeutics, Inc. Methods for inhibiting cognitive deterioration in adults with down's syndrome
EP1441739B1 (de) * 2001-10-26 2006-02-15 Akzo Nobel N.V. Verwendung von (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)-estra-4,9-dien-3-on zur behandlung von schweren depressionen
WO2003043640A2 (en) * 2001-11-23 2003-05-30 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
WO2004004653A2 (en) * 2002-07-02 2004-01-15 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferon-alpha therapy
WO2004054587A1 (en) * 2002-12-18 2004-07-01 University Of Zurich Treatment of neuro-psychiatric disorders
WO2004069202A2 (en) * 2003-02-04 2004-08-19 Corcept Therapeutics, Inc Antiglucocorticoids for the treatment of postpartum psychosis
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
US20090156565A1 (en) * 2004-12-03 2009-06-18 The Children's Hospital Of Philadelphia Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
CN100588393C (zh) * 2004-12-15 2010-02-10 上海三合生物技术有限公司 赛米司酮类用于治疗抑郁症的用途
US20060229505A1 (en) * 2005-04-08 2006-10-12 Mundt James C Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy
JP2009535430A (ja) * 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
EP1987814A1 (de) * 2007-04-30 2008-11-05 Exelgyn Pharmazeutische Mifepristonzusammensetzungen und Herstellungsverfahren dafür
RU2327448C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов
EP2155204B1 (de) * 2007-06-15 2016-08-17 Research Triangle Institute Androstan und pregnansteroid mit wirksamen eigenschaften zur modulation von gaba-rezeptor-chlorid-ionophor
US11103514B2 (en) * 2010-05-26 2021-08-31 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
JP5804395B2 (ja) 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
EP3265127B1 (de) * 2015-03-02 2024-02-21 Corcept Therapeutics, Inc. Mifepriston und octreotid zur verwendung bei der behandlung des cushing-syndroms bei einem patienten mit einem adrenocorticotropen hormon (acth) sezernierenden pankreatischen neuroendokrinen tumor
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
MX2017014857A (es) * 2015-05-18 2018-08-15 Corcept Therapeutics Inc Metodos para diagnosticar y evaluar tratamiento para sindrome de cushing.
CN109843183B (zh) * 2016-10-21 2022-04-12 西铁城时计株式会社 检测装置
US20220288091A1 (en) 2019-03-18 2022-09-15 Lynnette K. NIEMAN Method for Improving Insulin Sensitivity
JP7569492B2 (ja) 2019-12-11 2024-10-18 コーセプト セラピューティクス， インコーポレイテッド 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
US11878025B2 (en) * 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
CA2250874A1 (en) * 1996-04-09 1997-10-16 Btg International Limited Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs

Also Published As

Publication number Publication date
DK1023074T3 (da) 2006-11-06
US6150349A (en) 2000-11-21
JP2009132743A (ja) 2009-06-18
JP2001518509A (ja) 2001-10-16
PT1023074E (pt) 2006-12-29
KR20010024431A (ko) 2001-03-26
IL135469A0 (en) 2001-05-20
CA2302586C (en) 2008-06-10
DE69835225T2 (de) 2007-07-05
NO20001744D0 (no) 2000-04-05
CA2302586A1 (en) 1999-04-15
NO327233B1 (no) 2009-05-18
NZ503250A (en) 2001-09-28
ATE332696T1 (de) 2006-08-15
EP1023074B1 (de) 2006-07-12
CN1919199A (zh) 2007-02-28
IL135469A (en) 2007-03-08
ES2268792T3 (es) 2007-03-16
CY1106330T1 (el) 2011-10-12
KR100840957B1 (ko) 2008-06-24
NO20001744L (no) 2000-04-05
WO1999017779A1 (en) 1999-04-15
JP2009051858A (ja) 2009-03-12
KR100804558B1 (ko) 2008-02-20
CN1187053C (zh) 2005-02-02
CN1272788A (zh) 2000-11-08
CN1528315A (zh) 2004-09-15
JP5180125B2 (ja) 2013-04-10
US6362173B1 (en) 2002-03-26
AU747956B2 (en) 2002-05-30
EP1023074A1 (de) 2000-08-02
KR20070032822A (ko) 2007-03-22
AU9683298A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
DE69835225D1 (de) Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
DE69833502D1 (de) Glucocorticoid receptor antagonisten zur behandlung von demenz
ATE406166T1 (de) Verfahren zur prävention von gewichtszunahme infolge von antipsychotika
ATE425157T1 (de) Chemokin rezeptor bindenden heterozyklische verbindungen
NO20003552L (no) Progesteron-agonistforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsen, samt en fremgangsmÕte for bestemmelse av tilstedeværelse av steroidreseptorer, ligand-steroidreseptorkomplekser og en fremgangsmÕte
DE69709752D1 (de) Androgen rezeptor modulator verbindungen und verfahren
ATE377606T1 (de) Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
ATE529116T1 (de) Verfahren zur verstärkung des therapeutischen ansprechens auf elektrokonvulsive therapie (ect)
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
TW200621244A (en) Modulators of muscarinic receptors
NO20073369L (no) Modulatorer av muskarinreseptorer
HK1047050A1 (zh) 治疗轻度智力机能缺陷的方法
NO20006320L (no) Cykliske somatostatin-analoger
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
ATE492281T1 (de) Verwendung von glucocorticoid-rezeptor- spezifischen antagonisten zur behandlung von delirium
DE60325737D1 (de) Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen
ATE380048T1 (de) Behandlung der männlichen sexuellen dysfunktion
ATE408144T1 (de) Assays
ATE342055T1 (de) Verwendung von steroidalen estrogenrezeptorantagonisten zur männlichen fertilitätskontrolle
ATE320005T1 (de) Testverfahren für agonisten oder antagonisten der bindung von dynorphin a an den mas-rezeptor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition